Biodesix Publishes Data on New COVID-19 Artificial Intelligence (AI)-Based Algorithm for Use in Clinical Decision Support Systems
Summary
BOULDER, Co.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced a publication describing the development of a new AI-based COVID-19 algorithm and the important data from a related study. The machine learning, AI-based algorithm was developed using Biodesix’s Diagnostic Cortex® AI platform in close collaboration with a leading academic center to stratify hospitalized COVID-19 patients by risk of severe outcomes. “The ability to rapidly determine a patient’s risk of severe COVID disease, early, easily, and accurately, can help physicians to identify those who could benefit from specialized treatment and early interventions and get them the care they require in the optimal treatment window,” said Robert Georgantas III, Ph.D., Senior Vice President of Research and Translational Science at Biodesix. This ability is especially valuable now, during the pandemic, when timely treatment decisions are crucial and critical resources such as ICU beds and ventilators can be scarce.” Biodesix is working with a U.S.-based COVID-19 consortia and another international COVID-19 consortia consisting of major academic institutions to perform additional large, blinded, independent validation testing of the AI-based algorithm, and is currently exploring options for making this widely available for hospitals to incorporate into their clinical decision support systems. This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.